RA CAPITAL MANAGEMENT, L.P. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001346824

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q3 2026 · 88 positions · Total reported value $9.72B · Top-10 concentration 62.7% · Updated 2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

Turnover: 38.4% · 15 new · 12 cut · 11 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -13.6% · vs SPY -15.8% · Prev Value $11.51B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -1.6% · vs SPY -3.7% · Latest Value $9.72B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, RA CAPITAL MANAGEMENT, L.P. disclosed 88 equity positions with a combined reported value of $9.72B. The filing implies a focused portfolio: its ten largest positions account for 62.7% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were ASND ($2.34B), PBLS ($942.16M), PCVX ($652.90M). By sector, the heaviest allocations are Health Care 99.3%, Financials 0.3%. Versus the prior quarter, allocation shifted toward Health Care (+1.3pp) and away from Other (-1.2pp).

Versus the prior quarter, RA CAPITAL MANAGEMENT, L.P. opened 15 new positions, trimmed 12 and fully exited 11, a turnover rate of 38.4% of positions. The portfolio's overlap with the prior quarter was 74% of names.

The largest new positions opened in Q3 2026 were AMLX ($124.53M), VRDN ($81.79M), DBVT ($43.01M).

Of the 11 positions fully exited versus the prior quarter, the largest were BCRX ($158.27M), NUVL ($153.94M), NTLA ($76.60M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • AMLX AMYLYX PHARMACEUTICALS INC · $124.53M
  • VRDN VIRIDIAN THERAPEUTICS INC · $81.79M
  • DBVT DBV TECHNOLOGIES S A · $43.01M
  • AGEN AGENUS INC · $40.93M
  • SYRE SPYRE THERAPEUTICS INC · $33.17M
  • ANIX ANIXA BIOSCIENCES INC · $28.57M
  • GRTX ELECTRA THERAPEUTICS INC · $19.05M
  • SGMT SAGIMET BIOSCIENCES INC · $17.78M

Fully Exited (vs previous quarter)

  • BCRX BIOCRYST PHARMACEUTICALS INC · prev qtr: $158.27M
  • NUVL NUVALENT INC · prev qtr: $153.94M
  • NTLA INTELLIA THERAPEUTICS INC · prev qtr: $76.60M
  • DFTX DEFINIUM THERAPEUTICS INC · prev qtr: $70.56M
  • AKTS AKTIS ONCOLOGY INC · prev qtr: $42.36M
  • BIOA BIOAGE LABS INC · prev qtr: $40.97M
  • KPTI KARYOPHARM THERAPEUTICS INC · prev qtr: $18.73M
  • WAY WAYSTAR HLDG CORP · prev qtr: $10.87M

Insider Transactions (Form 4)

Latest RA CAPITAL MANAGEMENT, L.P. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-11-02 Buy Bambusa Therapeutics, Inc. 164,891 $16.00 SEC filing
2026-11-02 Buy Bambusa Therapeutics, Inc. 2,335,109 $16.00 SEC filing
2026-11-02 Conversion Bambusa Therapeutics, Inc. 1,331,080 — SEC filing
2026-11-02 Conversion Bambusa Therapeutics, Inc. 3,144,858 — SEC filing
2026-10-30 Buy Bambusa Therapeutics, Inc. 263,911 $14.92 SEC filing
2026-10-30 Buy Bambusa Therapeutics, Inc. 189,909 $14.23 SEC filing
2026-10-29 Sell LENZ Therapeutics, Inc. 107,170 $3.36 SEC filing
2026-10-29 Sell LENZ Therapeutics, Inc. 451,998 $3.36 SEC filing

All insider transactions →

Fund Profile

RA Capital Management is a Boston-based investment firm founded by Peter Kiernan, specializing in healthcare-focused investments with a long-term, value-oriented approach.

Investment Approach

Focuses on healthcare sector investments

Long-term, value-oriented strategy

Deep fundamental research and analysis

Asset Classes & Strategy

Primarily invests in public equities

Also manages private investments in healthcare companies

Concentrated portfolio approach with significant positions in healthcare companies

Key Personnel

Peter Kiernan: Founder and portfolio manager

Team of experienced investment professionals with healthcare expertise

Notable Facts

Founded in 2002

Manages approximately $16.4 billion in assets

Files SEC Form 13F for US equity positions

This profile is based on publicly available information and should not be considered as official disclosure from the firm.

AI Rebalance Analysis

1. Overall direction and market view: The fund increased its total portfolio value by $9716.0M, with a clear focus on adding positions in biotech/healthcare (PBLS, ARTV) while selectively reducing others (SEPN), suggesting a bullish stance on innovative therapeutics but with some profit-taking. 2. Key moves: - Added: PBLS (Parabilis Medicines, +2.82% weight), ARTV (Artiva Biotherapeutics, +0.76% weight). - Reduced: SEPT (Septerna, -21.3% shares sold, weight unchanged due to price effect). 3. Portfolio structure: Highly active, concentrated in Health Care (100% of top 10), with a preference for clinical-stage biotech/pharma, indicating high-risk, high-reward appetite. 4. Per-holding one-liner: - ASND: Ascendis Pharma (growth hormone disorders). - PBLS: Parabilis Medicines (unverified, likely biotech). - PCVX: Vaxcyte (vaccine development). - RYTM: Rhythm Pharmaceuticals (obesity/rare diseases). - EWTX: Edgewise Therapeutics (muscle disorders). - TYRA: Tyra Biosciences (unverified, likely oncology). - COAG: Hemab Therapeutics (hemophilia). - NAMS: NewAmsterdam Pharma (metabolic diseases). - ARTV: Artiva Biotherapeutics (unverified, likely immuno-oncology). - SEPN: Septerna (GI disorders). 5. Style summary: Aggressive biotech investor doubling down on high-potential clinical-stage names while trimming losers.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 09:28

Sector Allocation

Health Care 99.3%
Financials 0.3%
Materials 0.0%
Other 0.3%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 10.28M $2.34B 24.11%
24.11%
Hold
2 29.18M $942.16M 9.70%
9.70%
Add
3 11.47M $652.90M 6.72%
6.72%
Hold
4 6.67M $634.78M 6.53%
6.53%
Hold
5 8.39M $340.74M 3.51%
3.51%
Hold
6 12.20M $266.78M 2.75%
2.75%
Hold
7 7.81M $240.82M 2.48%
2.48%
Hold
8 9.55M $232.26M 2.39%
2.39%
Hold
9 23.79M $220.20M 2.27%
2.27%
Add
10 5.50M $215.33M 2.22%
2.22%
Reduce
11 8.02M $208.55M 2.15%
2.15%
Hold
12 11.19M $193.36M 1.99%
1.99%
Hold
13 7.69M $193.32M 1.99%
1.99%
Hold
14 2.45M $160.39M 1.65%
1.65%
Hold
15 30.44M $148.22M 1.53%
1.53%
Add
16 7.26M $135.03M 1.39%
1.39%
Hold
17 5.27M $131.59M 1.35%
1.35%
Hold
18 1.55M $129.48M 1.33%
1.33%
Hold
19 4.28M $124.53M 1.28%
1.28%
New
20 10.13M $116.19M 1.20%
Form 4 · 4 →
1.20%
Reduce
21 1.03M $102.00M 1.05%
1.05%
Reduce
22 26.98M $99.81M 1.03%
Form 4 · 1 →
1.03%
Hold
23 12.04M $87.02M 0.90%
0.90%
Hold
24 4.50M $85.93M 0.88%
Form 4 · 1 →
0.88%
Add
25 2.21M $84.77M 0.87%
0.87%
Hold
26 3.61M $84.74M 0.87%
0.87%
Reduce
27 5.96M $81.79M 0.84%
0.84%
New
28 2.82M $74.16M 0.76%
0.76%
Reduce
29 5.05M $72.26M 0.74%
0.74%
Hold
30 12.72M $66.92M 0.69%
0.69%
Hold
31 18.75M $54.66M 0.56%
0.56%
Hold
32 667.21K $53.16M 0.55%
0.55%
Hold
33 42.75M $52.59M 0.54%
0.54%
Hold
34 2.40M $51.07M 0.53%
0.53%
Hold
35 20.06M $48.56M 0.50%
0.50%
Hold
36 10.86M $46.81M 0.48%
0.48%
Hold
37 20.99M $46.60M 0.48%
0.48%
Hold
38 3.66M $43.01M 0.44%
0.44%
New
39 4.12M $40.93M 0.42%
0.42%
New
40 9.45M $39.10M 0.40%
0.40%
Hold
41 6.46M $33.96M 0.35%
0.35%
Reduce
42 1.80M $33.17M 0.34%
0.34%
New
43 17.75M $30.36M 0.31%
0.31%
Hold
44 3.49M $28.87M 0.30%
0.30%
Hold
45 892.74K $28.57M 0.29%
0.29%
New
46 3.01M $28.54M 0.29%
0.29%
Add
47 10.81M $28.31M 0.29%
0.29%
Hold
48 8.19M $27.29M 0.28%
0.28%
Add
49 1.84M $25.79M 0.27%
0.27%
Reduce
50 6.48M $25.32M 0.26%
0.26%
Hold

FAQ

What did RA CAPITAL MANAGEMENT, L.P. buy in 2026-Q3?

In its 2026-Q3 13F filing, RA CAPITAL MANAGEMENT, L.P. reported 88 equity positions worth $9.72B in aggregate; its largest disclosed positions were ASND ($2.34B), PBLS ($942.16M), PCVX ($652.90M).

How large is RA CAPITAL MANAGEMENT, L.P.'s portfolio?

RA CAPITAL MANAGEMENT, L.P. reported $9.72B of long equity holdings across 88 positions as of 2026-Q3. Top-10 holdings account for 62.7% of reported value.

What is RA CAPITAL MANAGEMENT, L.P.'s investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/ra-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →